Karolina Rzeniewicz
A5024366956- COVID-19 and healthcare impacts
- Cell Adhesion Molecules Research
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Chemokine receptors and signaling
- Immune Cell Function and Interaction
- Heparin-Induced Thrombocytopenia and Thrombosis
- Proteoglycans and glycosaminoglycans research
- Lung Cancer Research Studies
- Liver Disease Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Caveolin-1 and cellular processes
- Endoplasmic Reticulum Stress and Disease
- Angiogenesis and VEGF in Cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Neuroblastoma Research and Treatments
- Atherosclerosis and Cardiovascular Diseases
- Platelet Disorders and Treatments
- S100 Proteins and Annexins
- Neuroendocrine Tumor Research Advances
- Protease and Inhibitor Mechanisms
Hammersmith Hospital
2024
The Francis Crick Institute
2021
King's College London
2015-2021
University of Warwick
2021
British Heart Foundation
2015
Abstract Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is prospective cohort study of COVID-19 immunity patients with cancer. Here we evaluated 585 following administration two doses BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after were 85% and 59% solid hematological malignancies, respectively. A lower proportion had detectable titers neutralizing antibodies (NAbT) against severe acute...
Abstract Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported vaccines and is an extremely rare immune-related adverse event immune checkpoint inhibitors. We present a case CRS that occurred 5 d after BTN162b2 (tozinameran)—the Pfizer-BioNTech COVID-19 vaccine—in patient colorectal on long-standing anti-PD-1 monotherapy. The was...
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling clinical annotation. Of 357 patients cancer, 118 were SARS-CoV-2 positive, 94 symptomatic 2 died of COVID-19. In this cohort, 83% had S1-reactive antibodies 82% neutralizing against wild type SARS-CoV-2, whereas antibody titers Alpha, Beta Delta variants substantially reduced. levels decreased in 13% patients, remained stable for up to...
L-selectin is a cell adhesion molecule that tethers free-flowing leukocytes from the blood to luminal vessel walls, facilitating initial stages of their emigration circulation toward an extravascular inflammatory insult. Following shear-resistant wall, has frequently been reported be rapidly cleaved plasma membrane (known as ectodomain shedding), with little knowledge timing or functional consequence this event. Using advanced imaging techniques, we observe shedding occurring exclusively...
ABSTRACT The migration of circulating neutrophils towards damaged or infected tissue is absolutely critical to the inflammatory response. L-selectin a cell adhesion molecule abundantly expressed on neutrophils. For over two decades, neutrophil has been assigned exclusive role supporting tethering and rolling – initial stages multi-step cascade. Here, we provide direct evidence for contributing transendothelial (TEM). We show that co-clusters with PECAM-1 well-characterised involved in...
The migration of circulating leukocytes toward damaged tissue is absolutely fundamental to the inflammatory response, and transendothelial (TEM) describes first cellular barrier that breached in this process. Human CD14+ monocytes express L-selectin, bestowing a non-canonical role invasion during TEM. In vivo evidence supports for L-selectin regulating TEM chemotaxis, but intracellular mechanism poorly understood. ezrin-radixin-moesin (ERM) proteins anchor transmembrane cortical actin-based...
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study (NCT03226886) integrating longitudinal immune profiling clinical annotation. Of 357 patients cancer, 118 were SARS-CoV-2-positive, 94 symptomatic 2 died of COVID-19. In this cohort, 83% had S1-reactive antibodies, 82% neutralizing antibodies against WT, whereas antibody titers (NAbT) Alpha, Beta, Delta variants substantially reduced. Whereas levels decreased in 13% patients, NAbT...
Abstract CAPTURE (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 following administration two doses BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after were 85% and 59% solid hematological malignancies, respectively. A lower proportion had detectable neutralizing antibody titers (NAbT) against SARS-CoV-2 variants concern (VOCs) vs wild-type (WT). Patients malignancies more likely to have...
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Abstract We present a case of cytokine release syndrome (CRS) that occurred five days after vaccination with BTN162b2 (tozinameran), an mRNA COVID-19 vaccine, in patient colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated levels (IFN-y/IL-2R/IL-18/IL-16/IL-10), and steroid responsiveness.